Skin Cancer Risk Management in Patients Receiving Infliximab
Patients receiving infliximab require periodic skin examinations to monitor for melanoma, Merkel cell carcinoma, and non-melanoma skin cancers (NMSC), particularly those with prior phototherapy exposure or other skin cancer risk factors.
Key Monitoring Requirements
The FDA drug label explicitly warns that melanoma and Merkel cell carcinoma have been reported in patients treated with TNF-blocker therapy, including infliximab 1. Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer 1.
Specific Risk Considerations
Non-Melanoma Skin Cancer (NMSC):
- Psoriasis patients with prior prolonged phototherapy treatment are at highest risk 1
- In maintenance clinical trials, NMSCs were more common in patients with previous phototherapy 1
- The 2019 AAD-NPF guidelines note that some studies suggest an increased risk for NMSC in patients receiving TNF inhibitors 2
- One analysis showed a standardized incidence ratio (SIR) for NMSC of 1.51 (95% CI 1.04-2.11) in infliximab-treated patients 2
Melanoma and Other Malignancies:
- The FDA label specifically identifies melanoma as a concern requiring surveillance 1
- For other malignancies excluding NMSC, the SIR was 0.39 (95% CI 0.05-1.42) in one study of 1,373 psoriasis patients treated with infliximab 2
Cervical Cancer:
- A Swedish population-based study found a 2-3 fold increase in invasive cervical cancer incidence in women with rheumatoid arthritis treated with infliximab, particularly those over 60 years 1
- Periodic cervical cancer screening should continue in women treated with infliximab 1
Clinical Management Algorithm
Before Starting Infliximab:
- Perform baseline full-body skin examination
- Document any pre-existing skin lesions
- Assess phototherapy history (PUVA, UVB exposure)
- Review personal and family history of skin cancer
- Ensure age-appropriate cervical cancer screening is current for women
During Infliximab Treatment:
- Conduct periodic skin examinations at regular intervals 1
- Maintain heightened vigilance for patients with:
- Prior prolonged phototherapy 1
- History of NMSC
- Age >65 years
- Fair skin/high sun exposure history
Biopsy Threshold:
- Any atypical skin findings should prompt biopsy 2
- Lesions not responding appropriately to standard treatment warrant biopsy to rule out cutaneous T-cell lymphoma 2
Important Caveats
Context of Risk: While case reports document rapid development of multiple basal cell carcinomas 3 and squamous cell carcinomas 4 after infliximab initiation, the temporal relationship does not necessarily establish causality 5. A 2018 systematic review found that TNF inhibitor treatment is not associated with increased risks of overall cancer, lymphoma, or melanoma, though NMSC results were inconsistent 6.
Combination Therapy Considerations: The AAD-NPF guidelines note that acitretin may be combined with TNF inhibitors to potentially inhibit development of cutaneous squamous cell carcinoma in susceptible patients 7.
Patient Counseling: Patients should be educated about self-skin examination and instructed to report any new or changing lesions promptly.
The evidence supports a proactive surveillance approach rather than avoiding infliximab in appropriate candidates, as the overall malignancy risk (excluding NMSC) does not appear elevated compared to the general population or disease-matched controls 2.